Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Conditions
- Acute Promyelocytic Leukemia
Interventions
- DRUG: Tretinoin and Arsenic Trioxide
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]